SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Simcha Therapeutics (“Simcha”), a clinical-stage ...

Some 68% of patients with autoimmune disease had "major" side effects from CAR-T therapy for myeloma, lymphoma, or leukemia, ...

The 2025 ESMO annual meeting featured a metastatic castration-resistant prostate cancer (mCRPC) session and a presentation by ...

Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on ...

MIT and Harvard reserchers have developed immune-evading CAR-NK cells that eliminate cancer in mice while avoiding cytokine ...

GLP-1 receptor agonist therapy reduced surgical abscess repairs and hospitalizations among people with hidradenitis ...

Investigators employed the Accelerating Medicines Partnership to identify noninvasive biomarkers of lupus nephritis pathology and treatment response.

EyePoint (EYPT) announced details for its pivotal Phase 3 program evaluating Duravyu for the treatment of diabetic macular edema with first ...

Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies. The management of moderate ...

In a discovery that could expand the array of current cancer immunotherapy treatments, scientists at Harvard Medical School have identified a new molecular brake that hinders the ability of T cells to ...

Current cell therapies like CAR-T cells lack the precision to distinguish between healthy and diseased tissue, leading to limited effectiveness and potential side effects. One of the most significant ...

The authors addressed an important biological question, namely the role of glutamine metabolism in humoral responses, and they obtained solid conclusions. The strength of this study is that the ...